title: Antioxidant treatment restores prejunctional regulation of purinergic transmission in mesenteric arteries of deoxycorticosterone acetate-salt hypertensive rats.
abstract: Norepinephrine (NE) and ATP are co-released by periarterial sympathetic nerves. In mesenteric arteries (MA) from deoxycorticosterone-acetate (DOCA)-salt hypertensive rats, ATP, but not norepinephrine, release is impaired suggesting that their release may be regulated differently. We tested the hypothesis that different calcium channels contribute to ATP and norepinephrine release from sympathetic nerves in vitro in MA from normotensive and DOCA-salt hypertensive rats and that oxidative stress disrupts prejunctional regulation of co-transmission. Excitatory junction potentials (EJPs) were used to measure ATP release. Norepinephrine release was measured amperometrically with carbon-fiber microelectrodes. CdCl2 (30 microM) inhibited norepinephrine release in sham and DOCA-salt arteries by 78% and 85%, respectively. The N-type calcium channel antagonist, omega-conotoxin GVIA (CTX, 0.1 microM) inhibited norepinephrine release by 50% and 67% in normotensive and DOCA-salt arteries, respectively while CTX blocked EJPs. The P/Q-type calcium channel antagonist omega-agatoxin IVA (ATX; 0.03 microM) reduced norepinephrine release in sham but not DOCA-salt arteries and increased EJPs in sham but not DOCA-salt arteries. ATX did not increase EJPs in sham arteries in the presence of the alpha(2)-adrenergic receptor antagonist, yohimbine (1 microM). alpha(2)-Autoreceptor-sensitive EJP facilitation is impaired in DOCA-salt hypertension but this response is restored in DOCA-salt rats treated chronically with the antioxidant, apocynin. Apocynin restored alpha(2)-autoreceptor regulation of norepinephrine release. We conclude that ATP released from periarterial sympathetic nerves is controlled directly by N-type calcium channels. Norepinephrine release is controlled by N and P/Q type calcium channels. Norepinephrine release controlled by P/Q channels acts at alpha(2)-adrenergic receptors to inhibit norepinephrine release suggesting that there may be multiple pools of norepinephrine in periarterial sympathetic nerves. Regulation of norepinephrine release by alpha(2)-autoreceptors and P/Q-type channels is impaired in DOCA-salt hypertension and alpha(2)-autoreceptor function is disrupted by oxidative stress.
authors.affiliation: The Neuroscience Program, Michigan State University, East Lansing, MI 48824, USA.
authors.forename: S L
authors.initials: SL
authors.lastname: Demel
authors.forename: H
authors.initials: H
authors.lastname: Dong
authors.forename: G M
authors.initials: GM
authors.lastname: Swain
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.forename: D L
authors.initials: DL
authors.lastname: Kreulen
authors.forename: J J
authors.initials: JJ
authors.lastname: Galligan
mesh_terms: D000098:Acetophenones / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000502:physiology; D003900:Desoxycorticosterone; D006973:Hypertension / Q000139:chemically induced / Q000378:metabolism* / Q000503:physiopathology; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects* / Q000294:innervation / Q000378:metabolism; D009130:Muscle, Smooth / Q000187:drug effects / Q000294:innervation / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D018341:Receptors, Adrenergic, alpha-2 / Q000502:physiology; D011983:Receptors, Purinergic / Q000502:physiology*; D017673:Sodium Chloride, Dietary; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000378:metabolism; D009435:Synaptic Transmission; D020867:omega-Agatoxin IVA / Q000494:pharmacology; D020866:omega-Conotoxin GVIA / Q000494:pharmacology
chemical_list: D000098:Acetophenones; D000975:Antioxidants; D002121:Calcium Channel Blockers; D015220:Calcium Channels; D018341:Receptors, Adrenergic, alpha-2; D011983:Receptors, Purinergic; D017673:Sodium Chloride, Dietary; D020867:omega-Agatoxin IVA; D003900:Desoxycorticosterone; D000255:Adenosine Triphosphate; D020866:omega-Conotoxin GVIA; C056165:acetovanillone; D009638:Norepinephrine
references.citation: Hypertension. 2008 Aug;52(2):322-9
references.pmid: 18606906
references.citation: Clin Exp Hypertens A. 1985;7(11):1629-45
references.pmid: 4085138
references.citation: Am J Hypertens. 1995 Mar;8(3):287-93
references.pmid: 7794579
references.citation: Jpn Heart J. 1975 Jan;16(1):36-43
references.pmid: 1121143
references.citation: J Cardiovasc Pharmacol. 2007 Jul;50(1):9-16
references.pmid: 17666910
references.citation: Br J Pharmacol. 1996 Sep;119(1):49-56
references.pmid: 8872356
references.citation: Hypertension. 2007 Sep;50(3):547-56
references.pmid: 17646575
references.citation: Br J Pharmacol. 1993 Sep;110(1):281-8
references.pmid: 8106104
references.citation: J Physiol. 2007 Jul 15;582(Pt 2):745-54
references.pmid: 17510179
references.citation: Br J Pharmacol. 2004 May;142(2):267-74
references.pmid: 15155535
references.citation: J Physiol. 2007 Nov 1;584(Pt 3):819-34
references.pmid: 17761778
references.citation: Blood Vessels. 1987;24(3):94-9
references.pmid: 3593978
references.citation: J Hypertens Suppl. 1986 Oct;4(3):S189-92
references.pmid: 2431119
references.citation: Br J Pharmacol. 1998 Dec;125(8):1669-76
references.pmid: 9886758
references.citation: J Neurophysiol. 1993 Aug;70(2):610-20
references.pmid: 8410161
references.citation: Neuropharmacology. 2009 Feb;56(2):368-78
references.pmid: 18824011
references.citation: Auton Neurosci. 2003 Feb 28;104(1):47-57
references.pmid: 12559203
references.citation: Circulation. 2003 Feb 25;107(7):1053-8
references.pmid: 12600921
references.citation: Pflugers Arch. 1995 Oct;430(6):901-8
references.pmid: 8594542
references.citation: Cardiovasc Res. 1998 Aug;39(2):492-505
references.pmid: 9798534
references.citation: Br J Pharmacol. 2005 Feb;144(4):519-27
references.pmid: 15678093
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1992 Aug;346(2):173-86
references.pmid: 1360152
references.citation: J Neurochem. 2008 Jan;104(2):298-305
references.pmid: 17961149
references.citation: J Pharmacol Exp Ther. 2002 Nov;303(2):439-44
references.pmid: 12388622
references.citation: J Cardiovasc Pharmacol. 1986;8 Suppl 5:S39-43
references.pmid: 2427882
references.citation: Auton Neurosci. 2009 Dec 3;151(2):90-7
references.pmid: 19716351
references.citation: Clin Exp Pharmacol Physiol. 1989 Apr;16(4):333-9
references.pmid: 2568204
references.citation: Hypertension. 1991 Nov;18(5 Suppl):III22-30
references.pmid: 1937684
references.citation: Br J Pharmacol. 1997 Feb;120(3):393-8
references.pmid: 9031741
references.citation: Br J Pharmacol. 2001 Mar;132(6):1201-8
references.pmid: 11250870
references.citation: J Neurosci. 1996 Jul 1;16(13):4155-61
references.pmid: 8753877
references.citation: Hypertension. 2004 May;43(5):1048-54
references.pmid: 15051669
references.citation: Br J Pharmacol. 1999 Jan;126(1):11-8
references.pmid: 10051115
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1993 Oct;348(4):358-66
references.pmid: 7904050
references.citation: Br J Pharmacol. 1999 Sep;128(1):174-80
references.pmid: 10498849
references.citation: Br J Pharmacol. 1990 May;100(1):180-4
references.pmid: 2372658
references.citation: Exp Physiol. 2009 Jan;94(1):25-30
references.pmid: 18805863
references.citation: Clin Sci (Lond). 2006 Feb;110(2):243-53
references.pmid: 16271043
references.citation: Br J Pharmacol. 2000 Jan;129(1):47-52
references.pmid: 10694201
references.citation: Prog Neurobiol. 1995 Sep;47(1):45-94
references.pmid: 8570853
references.citation: Clin Exp Pharmacol Physiol. 2007 Jul;34(7):601-5
references.pmid: 17581215
references.citation: Jpn Heart J. 1989 Mar;30(2):231-9
references.pmid: 2542635
references.citation: J Pharmacol Exp Ther. 1997 Aug;282(2):691-8
references.pmid: 9262332
references.citation: J Pharmacol Exp Ther. 1999 Jul;290(1):241-6
references.pmid: 10381782
references.citation: Br J Pharmacol. 1999 Dec;128(7):1602-8
references.pmid: 10602342